In this context, another modified recombinant human endostatin, known as Endostar, carries an N-terminal His-tag and was expressed in E. coli. China’s State Food and Drug Administration (SFDA) approved it for the treatment of non-small-cell lung carcinoma in 2005 [17]. This evidence concerns the gene COL18A1 and non-small cell lung carcinoma.